Molecular imaging of cancer with positron emission tomography

Nature Reviews Cancer

Volumn 2, Issue 9, 2002, Pages 683-693

  Gambhir, Sanjiv Sam ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT; OXYGEN; TRACER; TUMOR ANTIGEN;

BONE REMODELING; CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; GLUCOSE UTILIZATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; ISOTOPE LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR GENE; REPORTER GENE; REVIEW; THREE DIMENSIONAL IMAGING; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PHARMACOKINETICS;

ANIMALS; ANTIGENS, NEOPLASM; BONE REMODELING; FLUORODEOXYGLUCOSE F18; GENE THERAPY; GLUCOSE; HUMANS; NEOPLASMS; OXYGEN; PHARMACOKINETICS; RADIOACTIVE TRACERS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036717382     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc882     Document Type: Review

References (105)

1. Phelps, M. E., Hoffman, E. J., Mullani, N. A. & Ter-Pogossian, M. M. Application of annihilation coincidence detection to transaxial reconstruction. J. Nucl. Med. 16, 210-224 (1975).
2. Strijckmans, K. The isochronous cyclotron: principles and recent developments. Comput. Med. Imaging Graph. 25, 69-78 (2001).
3. Rosenthal, M. S. et al. Quantitative SPECT imaging: a review and recommendations by the Focus Committee of the Society of Nuclear Medicine Computer and Instrumentation Council. J. Nucl. Med. 36, 1489-1513 (1995).
4. Cherry, S. R. & Gambhir, S. S. Use of positron emission tomography in animal research. Ilar J. 42, 219-232 (2001). Describes the use of animal PET technology and its many applications.
5. Chatziioannou, A., Tai, Y. C., Doshi, N. & Cherry, S. R. Detector development for microPET II: a 1 micron resolution PET scanner for small animal imaging. Phys. Med. Biol. 46, 2899-2910 (2001).
6. Chatziioannou, A. F. Molecular imaging of small animals with dedicated PET tomographs. Eur. J. Nucl. Med. 29, 98-114 (2002).
7. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nature Rev. Cancer 2, 11-18 (2002).
8. Cutler, C. S., Lewis, J. S. & Anderson, C. J. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Adv. Drug Deliv. Rev. 37, 189-211 (1999).
9. Woodward, G. E. & Hudson, M. T. Cancer Res. 14, 599-605 (1954).
10. 14C] deoxyglucose to measure glucose utilization, which is the basis for the eventual development of a PET-compatible tracer (FDG).
11. 14C-2-deoxy-2-fluoro-D-glucose. J. Labeled Compounds Radiopharmacol. 14, 175-183 (1978).
12. Di Chiro, G. et al. in Positron Emission Tomography (eds Greitz, T., Ingvar, D. H. & Widen, L.) 351-361 (Raven, New York, 1985).
13. 18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol. 22, 360-371 (1987).
14. Kubota, K. et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J. Nucl. Med. 31, 1927-1932 (1990).
15. Gupta, N. C. et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 184, 441-444 (1992).
16. 18F]fluoro-2-deoxy-D-glucose. J. Comput. Assist. Tomogr. 17, 582-589 (1993).
17. Smith, T. A. Mammalian hexokinases and their abnormal expression in cancer. Br. J. Biomed. Sci. 57, 170-178 (2000).
18. Smith, T. A. FDG uptake, tumour characteristics and response to therapy: a review. Nucl. Med. Commun. 19, 97-105 (1998)
19. 3H-2-deoxyglucose retention in murine tumor models. Nucl. Med. Biol. 23, 533-541 (1996).
20. 18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl. Med. Biol. 28, 1-4 (2001).
21. Gambhir, S. S. et al. A tabulated summary of the FDG PET literature. J. Nucl. Med. 42, 1S-93S (2001). Describes in detail the accuracy of FDG PET in many different applications, including all major cancers.
22. Gambhir, S. S. et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J. Clin. Oncol. 16, 2113-2125 (1998).
23. Scott, W. J., Shepherd, J. & Gambhir, S. S. Cost-effectiveness of FDG-PET forstaging non-small cell lung cancer: a decision analysis. Ann. Thorac. Surg. 66, 1876-1883; discussion 1883-1885 (1998).
24. Huebner, R. H. et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colerectal cancer. J. Nucl. Med. 41, 1177-1189 (2000).
25. Park, K. C. et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann. Surg. 233, 310-319 (2001).
26. Schwimmer, J. et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q. J. Nucl. Med. 44, 153-167 (2000).
27. Delbeke, D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J. Nucl. Med. 40, 591-603 (1999).
28. Lapela, M. et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur. J. Cancer 36, 858-867 (2000).
29. Akhurst, T. et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann. Thoracic Surg. 73, 259-264 (2002).
30. Seltzer, M. A. et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer J. Urol. 162, 1322-1328 (1999).
31. Schroder, W., Zimny, M., Rudlowski, C., Bull, U. & Rath, W. The role of F-18-fluoro-deoxyglucose positron emission tomography (F-18-FDG PET) in diagnosis of ovarian cancer. Int. J. Gynecol. Cancer 9, 117-122 (1999).
32. Shields, A. F., Grierson, J. R., Kozawa, S. M. & Zheng, M. Development of labeled thymidine analogues for imaging tumor proliferation. Nucl. Med. Biol. 23, 17-22 (1996). Describes tracer approaches to the imaging of DNA synthetic rates.
33. Krohn, K. A., Mankoff, D. A. & Eary, J. F. Imaging cellular proliferation as a measure of response to therapy. J. Clin. Pharmacol. Suppl. 96S-103S (2001).
34. Shields, A. F. et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med. 4, 1334-1336 (1998).
35. 99mTc-methylene diphosphonate. Semin. Nucl. Med. 31, 28-49 (2001).
36. Ohta, M. et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with Tc-99(m)-MDP bone scintigraphy. Nucl. Med. Commun. 22, 875-879 (2001).
37. 18F]fluoride ion PET. J. Nucl. Med. 42, 1091-1100 (2001).
38. Narita, N. et al. Distribution of fluoride concentration in the rat's bone. Calcif. Tissue Int. 46, 200-204 (1990).
39. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
40. 15O: practical considerations. Nucl. Med. Biol. 27, 671-676 (2000).
41. Weber. W. A. et al. Tumor angiogenesis targeting using imaging agents, Q. J. Nucl. Med. 45, 179-182 (2001).
42. Koh, W. J. et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. Radiat. Oncol. Biol. Phys. 33, 391-398 (1995).
43. Nunn, A., Linder, K. & Strauss, H. W. Nitroimidazoles and imaging hypoxia. Eur. J. Nucl. Med. 22, 265-280 (1995).
44. Fujibayashi, Y. et al. Copper-62-ATSM: a new hypoxia Imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 38, 1155-1160 (1997).
45. 11C-N-methylspiperone. J. Comput. Assist. Tomogr. 10, 175-180 (1986).
46. 18F]fluoro-ethyl-spiperone. Eur. J. Nucl. Med. 24, 1149-1155 (1997).
47. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 42, 213-221 (2001).
48. 68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J. Nucl. Med. 42, 1053-1056 (2001).
49. 125I] IUDR. Nucl. Med. Biol. 28, 451-458 (2001).
50. 18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET. Nucl. Med. Biol. 24, 127-134 (1997).
51. Kortt, A. A., Dolezal, O., Power, B. E. & Hudson, P. J. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 18, 95-108 (2001).
52. Wu, A. M. et al. High-resolution microPET Imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. USA 97, 8495-8500 (2000). Describes the use of minibodies and diabodies for imaging in small-animal models.
53. Wu, A. M. & Yazaki, P. J. Designer genes: recombinant antibody fragments for biological imaging. Q. J. Nucl. Med. 44, 268-283 (2000).
54. Katzenellenbogen, J. A. Designing steriod receptor-based radiotracers to image breast and prostate cancer. J. Nucl. Med. 36 (Suppl.), 8-13 (1995).
55. Dehdashti, F. et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J. Nucl. Med. 36, 1766-1774 (1995).
56. 18F]fluoro-17β-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin. Cancer Res. 2, 933-939 (1996).
57. Flanagan, F. L. et al. PET assessment of response to tamoxifen therapy in patients with metastatic breast cancer. J. Nucl. Med. 37, 99P (1996).
58. Bonasera, T. A. et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J. Nucl. Med. 37, 1009-1015 (1996).
59. Downer, J. B. et al. Comparison of animal models for the evaluation of radiolabeled androgens. Nucl. Med. Biol. 28, 613-626 (2001).
60. Ray, P. et al. Monitoring gene therapy with reporter gene imaging. Semin. Nucl. Med. 31, 312-320 (2001).
61. Yu, Y. et al. Quantification of target gene expression by imaging reporter gene expression in living animals. Nature Med. 6, 933-937 (2000). Describes the imaging of a reporter gene linked to a therapeutic gene in order to quantify therapeutic gene expression indirectly.
62. Liang, Q. et al. Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. Mol. Ther. 6, 73-82 (2002).
63. Sun, X. et al. Quantitative imaging of gene induction in living animals. Gene Ther. 8, 1572-1579 (2001).
64. Yaghoubi, S. S. et al. Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors. Gene Ther. 8. 1072-1080 (2001).
65. Jacobs, A. et al. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia 1, 154-161 (1999).
66. Tjuvajev, J. G. et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 58, 4333-4341 (1998).
67. Gambhir, S. S. et al. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J. Nucl. Med. 39, 2003-2011 (1998).
68. Gambhir, S. S. et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc. Natl Acad. Sci. USA 96, 2333-2338 (1999). Describes the use of a PET reporter gene carried in an adenovirus to image virus-mediated gene delivery and expression in living mice.
69. MacLaren, D. C. et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 6, 785-791 (1999).
70. Gambhir, S. S. et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography Proc. Natl Acad. Sci. USA 97, 2785-2790 (2000).
71. Liang, Q. et al. Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther. 8, 1490-1498 (2001).
72. Gambhir, S. S. et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2, 118-138 (2000).
73. Moolten, F. L. Suicide genes for cancer therapy. Sci. Med. 4, 16-25 (1997).
74. 18F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J. Nucl. Med. 42, 1225-1234 (2001).
75. Jacobs, A. et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358, 727-729 (2001).
76. Hara, T., Kosaka, N. & Kishi, H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med. 39, 990-995 (1998).
77. Kotzerke, J. et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur. J. Nucl. Med. 27, 1415-1419 (2000).
78. 18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J. Urol. 168, 273-280 (2002).
79. Jager, P. L. et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J. Nucl. Med. 42, 432-445 (2001).
80. Tavitian, B. et al. In vivo imaging of oligonucleotides with positron emission tomography. Nature Med. 4, 467-471 (1998).
81. Tavitian, B. In vivo antisense imaging. Q. J. Nucl. Med. 44, 236-255 (2000).
82. Hnatowich, D. J. Antisense imaging: where are we now? Cancer Biother. Radiopharm. 15, 447-457 2000).
83. Paulmurugan, R., Umezawa, Y. & Gambhir, S. S. Imaging protein-protein interactions in living subjects by a reporter protein reconstitution and complementation strategies. Mol. Imaging Biol. (in the press).
84. Liu, X. et al. Partial correction of endogenous ΔF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nature Biotechnol. 20, 47-52 (2002).
85. Puttaraju, M., DiPasquale, J., Baker, C. C., Mitchell, L. G. & Garcia-Blanco, M. A. Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA transsplicing Mol. Ther. 4, 105-114 (2001).
86. Bhaumik, S., Lewis, X., Puttaraju, M., Mitchell, L. G. & Gambhir, S. S. Imaging mRNA levels in living animals through a novel RNA trans-splicing signal amplification approach Mol. Imaging Biol. (in the press).
87. Becker-Hapak, M., McAllister, S. S. & Dowdy, S. F. TAT-mediated protein transduction into mammalian cells Methods 24, 247-256 (2001).
88. Lewis, J. S. et al. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. Eur. J. Nucl. Med. 27, 638-646 (2000).
89. 18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer: a feasibility study. J. Surg. Res. 97, 9-13 (2001).
90. Silverman, D. H. et al. Evaluating tumor biology and oncological disease with positron-emission tomography. Semin. Radiat. Oncol 8, 183-196 (1998).
91. Krohn, K. A. Evaluation of alternative approaches for imaging cellular growth. Q. J. Nucl. Med. 45, 174-178 (2001).
92. Townsend, D. W. & Cherry, S. R. Combining anatomy and function: the path to true image fusion. Eur Radiol. 11, 1968-1974 (2001).
93. Townsend, D. W. A combined PET/CT scanner: the choices. J. Nucl. Med. 42, 533-534 (2001). Describes the PET/CT technology to perform simultaneous functional and anatomical imaging in patients.
94. Ell, P. J. & Von Schulthess, G. K. PET/CT: a new road map. Eur. J. Nucl. Med. Mol. Imaging 29, 719-720 (2002).
95. Kluetz, P. G. et al. Combined PET/CT imaging in oncology. Impact on patient management. Clin. Positron Imaging 3, 223-230 (2000).
96. Paulus, M. J., Gleason, S. S., Kennel, S. J., Hunsicker, P. R. & Johnson, D. K. High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia 2, 62-70 (2000).
97. Paulus, M. J., Gleason, S. S., Easterly, M. E. & Foltz, C. J. A review of high-resolution X-ray computed tomography and other imaging modalities for small animal research. Lab. Anim. 30, 36-45 (2001).
98. Berger, F. et al. Whole body skeletal imaging in mice using MicroPET and MicroCAT: new tools for small animal bone imaging. Eur. J. Nucl. Med. (in the press).
99. Shao, Y. et al Simultaneous PET and MR imaging. Phys. Med. Biol. 42, 1965-1970 (1997).
100. Vaalburg, W., Hendrikse, N. H. & de Vries, E. F. Drug development, radiolabelled drugs and PET Ann. Med. 31, 432-437 (1999).
101. Cherry, S. R. Fundamentals of positron emission tomography and applications in preclinical drug development. J. Clin. Pharmacol. 41, 482-491 (2001).
102. Price, P. Monitoring response to treatment in the development of anticancer drugs using PET. Nucl. Med. Biol. 27, 691 (2000).
103. Katz, R., Wagner, H. N., Fauntleroy, M., Kuwert, T. & Frank, R. The use of imaging as biomarkers in drug development: regulatory issues worldwide. J. Clin. Pharmacol. Suppl. 118S (2001).
104. Paans, A. M. & Vaalburg, W. Positron emission tomography in drug development and drug evaluation. Curr. Pharm. Des. 6, 1583-1591 (2000).
105. Fowler J. S., Volkow, N. D., Wang, G. J., Ding, Y. S. & Dewey, S. L. PET and drug research and development. J. Nucl. Med. 40, 1154-1163 (1999).